The FDA determined the condition qualifies as a rare pediatric disease because it is a serious disorder that primarily affects patients from birth through age 18, Vanda said. The ...
European regulators recommended that a skin disease treatment developed by Vanda Pharmaceuticals receive orphan drug designation. Vanda said Thursday that the European Medicines Agency's Committee for ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
Pharmaceutical Technology on MSN
FDA grants rare paediatric designation to Vanda’s CMT2S therapy
The status was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.
WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for ...
Asianet Newsable on MSN
VNDA stock gains after-hours as FDA grants rare pediatric disease designation for experimental therapy
The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S.
WASHINGTON, Jan. 23, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug ...
In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results